However, due to the immunosuppressive tumor microenvironment (TME) of OC, monotherapy with immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 has not achieved therapeutic effects to the satisfaction of investigators when compared to the effects of targeted agents (Kandalaft et al., 2019). The gene discussed is CD274; the disease is neoplasm.